Testing for Eligibility
Tumor gene testing by a designated lab is the only pathway for new patients to enroll into the trial. The laboratory referral process applies to eligible cancer patients who have their tumors genomically profiled by a designated laboratory at one of the nearly 1100 clinical sites across the United States. NeoGenomics is a designated laboratory for NCI-MATCH. NeoGenomics provides 19 different NeoTYPE® Solid Tumor Profiles that may qualify a patient for the study. There are two pan-tumor (broad) Profiles and 17 targeted (tumor-specific) Profiles as shown below. The NeoTYPE Discovery Profile is a common choice for clinical trial screening because it is our most comprehensive Profile, evaluating 323 genes by next-generation sequencing (NGS).
Primary ID EAY131
Secondary IDs NCI-2015-00054
Clinicaltrials.gov ID NCT02465060
Call Client Services to order a NeoTYPE® Solid Tumor Profile or to request historical review of NeoTYPE® Discovery Profile for potential NCI-MATCH eligibility at 866.776.5907, option 3.
Contact Us To Get Started!
Work with us – your premier oncology partner – to optimize cancer care for patients